Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response’s statements about increased mortality in elderly patients with dementia-related psychosis are directly supported by Section 5.1, including the note that VRAYLAR is not approved for that indication. Statements about suicidal thoughts/behaviors are supported but appropriately scoped to the label’s antidepressant-trial/monitoring and pediatric MDD adjunctive context.
Category Scores
Accurate Statements
Increased mortality in elderly patients with dementia-related psychosis: antipsychotic drugs increase all-cause risk of death; VRAYLAR is not approved for dementia-related psychosis.
Section 5.1
Suicidal thoughts/behaviors: label describes increased incidence in antidepressant-treated patients age 24 years and younger and includes monitoring/counseling and consideration of changing/discontinuing VRAYLAR if emergent suicidal thoughts/behaviors occur.
Section 5.2
Pediatric use context for suicidal thoughts/behaviors with antidepressants: section 8.4 reiterates antidepressants increase risk in pediatric patients for MDD adjunctive therapy.
Section 8.4
Unsupported Statements
Contradictions
Important Omissions
No monitoring/boxed-warning language was missing for the specific claims evaluated; however, the provided evaluation does not explicitly quote or name the boxed warning text for either warning, relying instead on section references.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluation accurately reflects FDA label warnings relevant to the claimed topics and does not introduce unsupported causal claims beyond what the label frames.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suicidal thoughts/behaviors support is limited to the label’s antidepressant-trial/monitoring and pediatric MDD adjunctive contexts; broader standalone causality for VRAYLAR is not explicitly stated in the provided label excerpts.
Suggested Improvement
Explicitly state that the label frames suicidal thoughts/behaviors risk in relation to antidepressant treatment/clinical monitoring and pediatric MDD adjunctive therapy, rather than implying an independent VRAYLAR-only mechanism outside that context.